111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
不同剂量布托啡诺对卵巢癌减瘤术患者围手术期镇痛、恢复及免疫功能影响的随机对照试验
Authors Wang G, Xu M, Li C, Zhang N , Tian T, Gao C , Zhang W
Received 17 June 2025
Accepted for publication 19 November 2025
Published 8 December 2025 Volume 2025:19 Pages 10885—10897
DOI https://doi.org/10.2147/DDDT.S545111
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Muzammal Hussain
Guizhi Wang,1 Mengmeng Xu,2 Chuanyao Li,2 Na Zhang,2 Tingting Tian,2 Chen Gao,2 Wei Zhang1,2
1Graduate School, Bengbu Medical University, Bengbu, Anhui, People’s Republic of China; 2Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China
Correspondence: Wei Zhang, Graduate School, Bengbu Medical University, 2600 Donghai Avenue, Bengbu, Anhui, 233030, People’s Republic of China, Email doctor_zw97079@163.com Chen Gao, Department of Anesthesiology, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People’s Republic of China, Email gaochen8805@126.com
Purpose: To investigate the optimal dose of butorphanol for patient-controlled intravenous analgesia (PCIA) by evaluating its effects on perioperative pain control and immune function in patients undergoing ovarian cancer surgery.
Patients and Methods: Patients undergoing ovarian cancer surgery between May 2023 and March 2025 were randomized into four PCIA groups: Group S (sufentanil 0.04 μg·kg− 1·h− 1), B1 (low-dose butorphanol 3.0 μg·kg− 1·h− 1), B2 (medium-dose butorphanol 3.5 μg·kg− 1·h− 1), and B3 (high-dose butorphanol 4.0 μg·kg− 1·h− 1). Postoperative pain visual analog scale scores (VAS) were recorded for each group at T1 (2 h), T2 (6 h), T3 (12 h), T4 (24 h), and T5 (48 h). The number of PCIA button presses, rescue analgesia frequency, adverse reactions, inflammatory biomarkers, postoperative recovery indicators, and the level of lymphocyte subsets and NK cells were recorded.
Results: VAS score at T3 was lower in group B3 than in S (P = 0.042). VAS scores at T3 and T4 were lower in groups B2 (P = 0.007 and P < 0.001) and B3 (P = 0.005 and P < 0.001) than in B1. Compared to group S, B1 showed an increased area under the curve of VAS time (AUCVAS-time) over 48 hours (P = 0.010), whereas group B3 exhibited a decrease in AUCVAS-time (P = 0.004). Group B3 had shorter postoperative time to ambulate than group S (P = 0.041). In group S, NK cells at T5 were lower than those at T0 (P = 0.007). In group B1, levels of CD4+ T cells, and CD4+/CD8+ ratio were higher at T5 than at T0 (P = 0.007 and P = 0.014), whereas CD8+ T cell count was lower (P = 0.011).
Conclusion: High-dose butorphanol PCIA effectively relieves postoperative pain and reduces time to early ambulation without affecting immune indicators within 48 h postoperatively.
Keywords: butorphanol, postoperative analgesia, cytoreductive surgery, immune function
1Graduate School, Bengbu Medical University, Bengbu, Anhui, People’s Republic of China; 2Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China
Correspondence: Wei Zhang, Graduate School, Bengbu Medical University, 2600 Donghai Avenue, Bengbu, Anhui, 233030, People’s Republic of China, Email doctor_zw97079@163.com Chen Gao, Department of Anesthesiology, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People’s Republic of China, Email gaochen8805@126.com
Purpose: To investigate the optimal dose of butorphanol for patient-controlled intravenous analgesia (PCIA) by evaluating its effects on perioperative pain control and immune function in patients undergoing ovarian cancer surgery.
Patients and Methods: Patients undergoing ovarian cancer surgery between May 2023 and March 2025 were randomized into four PCIA groups: Group S (sufentanil 0.04 μg·kg− 1·h− 1), B1 (low-dose butorphanol 3.0 μg·kg− 1·h− 1), B2 (medium-dose butorphanol 3.5 μg·kg− 1·h− 1), and B3 (high-dose butorphanol 4.0 μg·kg− 1·h− 1). Postoperative pain visual analog scale scores (VAS) were recorded for each group at T1 (2 h), T2 (6 h), T3 (12 h), T4 (24 h), and T5 (48 h). The number of PCIA button presses, rescue analgesia frequency, adverse reactions, inflammatory biomarkers, postoperative recovery indicators, and the level of lymphocyte subsets and NK cells were recorded.
Results: VAS score at T3 was lower in group B3 than in S (P = 0.042). VAS scores at T3 and T4 were lower in groups B2 (P = 0.007 and P < 0.001) and B3 (P = 0.005 and P < 0.001) than in B1. Compared to group S, B1 showed an increased area under the curve of VAS time (AUCVAS-time) over 48 hours (P = 0.010), whereas group B3 exhibited a decrease in AUCVAS-time (P = 0.004). Group B3 had shorter postoperative time to ambulate than group S (P = 0.041). In group S, NK cells at T5 were lower than those at T0 (P = 0.007). In group B1, levels of CD4+ T cells, and CD4+/CD8+ ratio were higher at T5 than at T0 (P = 0.007 and P = 0.014), whereas CD8+ T cell count was lower (P = 0.011).
Conclusion: High-dose butorphanol PCIA effectively relieves postoperative pain and reduces time to early ambulation without affecting immune indicators within 48 h postoperatively.
Keywords: butorphanol, postoperative analgesia, cytoreductive surgery, immune function